Leerink Partnrs Predicts Lantheus’ Q1 Earnings (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Lantheus in a research report issued to clients and investors on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz expects that the medical equipment provider will post earnings per share of $1.32 for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS, Q4 2025 earnings at $1.57 EPS and FY2025 earnings at $5.77 EPS.

A number of other equities research analysts have also issued reports on LNTH. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $80.88 on Thursday. The stock has a market cap of $5.62 billion, a PE ratio of 13.46 and a beta of 0.44. Lantheus has a 1 year low of $56.06 and a 1 year high of $126.89. The firm has a fifty day moving average price of $90.60 and a 200-day moving average price of $97.20.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after buying an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after acquiring an additional 2,361,000 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the period. Finally, Reinhart Partners LLC. grew its holdings in Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.